Full-Time

Scientist II

Radiochemistry

Posted on 9/30/2024

Telix Pharmaceuticals

Telix Pharmaceuticals

201-500 employees

Develops targeted radiation therapies for cancer

Biotechnology
Healthcare

Mid

Remote in USA

Category
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary
Requirements
  • Bachelor’s degree plus 5+ years' experience, or Masters degree plus 3+ years' experience required
  • GMP level radiochemistry experience is required
  • Experience transferring HPLC, TLC, or GC QC methods for radiopharmaceuticals is required
  • Experience working on GMP-compliant manufacturing is required
  • Strong written and verbal communication skills are required
  • Experience working with fluorine and iodine radiochemistry is preferred
  • Experience of method/process development to support regulatory filings is preferred
Responsibilities
  • Interface with key stakeholders, including external CMOs, to manage the development of manufacturing and QC procedures for clinical and commercial stage radiopharmaceutical assets in compliance with all applicable GMP regulations.
  • Manage the manufacturing and analytical method transfer process to new manufacturing facilities.
  • Manage the development and validation of manual or automated manufacturing procedures as required.
  • Manage the development and validation of non-compendial QC procedures as required.
  • Generate development, validation, method transfer, and various other types of protocols and reports to support regulatory filings for commercial drug products.
  • Support regulatory filings via completion of CMC sections for INDs, NDAs, and foreign equivalents.
  • Generate SOPs for manufacturing and QC procedures.
  • Provide technical support for manufacturing and QC procedures for all Telix products as required.
  • Ensure all documentation generated is consistent with Telix QMS and general principles of GMP manufacturing.
Telix Pharmaceuticals

Telix Pharmaceuticals

View

Telix Pharmaceuticals develops and sells products for diagnosing and treating cancer and rare diseases using targeted radiation. Their products help healthcare providers make better treatment decisions and offer personalized therapy for patients with significant medical needs. The company focuses on areas like prostate and kidney cancers, glioma, sarcoma, and bone marrow conditioning. Telix has a strong global supply chain to ensure their products are available to healthcare institutions and professionals. Unlike many competitors, Telix emphasizes sustainability, patient care, and ethical practices in its operations. The goal of Telix Pharmaceuticals is to improve the quality of life for patients by providing advanced diagnostic and therapeutic solutions.

Company Stage

IPO

Total Funding

$14.8M

Headquarters

Melbourne, Australia

Founded

2015

Growth & Insights
Headcount

6 month growth

18%

1 year growth

43%

2 year growth

106%
Simplify Jobs

Simplify's Take

What believers are saying

  • Telix's acquisition of RLS expands its North American manufacturing and distribution capabilities.
  • The radiopharmaceutical market is projected to grow to $14 billion by 2032.
  • FDA Fast Track designation for TLX101-CDx could expedite its market entry.

What critics are saying

  • Increased competition from companies like Lantheus in the theranostics field.
  • Retirement of co-founder Andreas Kluge may impact strategic direction.
  • Acquisition of RLS could strain financial resources and pose integration challenges.

What makes Telix Pharmaceuticals unique

  • Telix focuses on molecularly-targeted radiation therapy for prostate, renal, and glioblastoma cancers.
  • The company integrates diagnostics and therapy, offering personalized treatment for complex diseases.
  • Telix's global supply chain ensures product availability and delivery worldwide.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE